On July 30, 2026 Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, reported financial results for the quarter ended June 30, 2026.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Q2 was another exceptional quarter for us," said Eric Lefkofsky, Founder and CEO of Tempus. "Our strategy is working given the investments we have made in AI over the past several years are driving some of the best growth rates we have seen in our two largest businesses – Oncology Diagnostics and Data Licensing."
Second Quarter 2026 Highlights
Total revenue of $382.5 million, up 22% year-over-year
Oncology volume growth of 31% year-over-year, up from 28% last quarter
Molecular residual disease (MRD) volume was 9,000 tests, up from 6,500 last quarter
Data Licensing & Modeling (Insights) revenue up 36% year-over-year
Signed ~$200 million in new Data and Applications licenses
FDA approved xT Tumor Only which will migrate tissue testing to ADLT pricing
Successfully delivered our first oncology foundation model to AstraZeneca
Completed a $460 million offering of 0.0% convertible senior notes due 2032
GAAP net income of $5.6 million and Adjusted EBITDA of $8.0 million
Cash and marketable securities of $820.7 million as of June 30, 2026
Increasing revenue guidance to $1.595 to $1.605 billion for 2026 and expect full year Adjusted EBITDA of ~$65 million
On July 20, 2026, Tempus also announced an agreement to acquire Personalis, a leader in the tumor-informed MRD space. "Through our existing collaboration with Personalis, we have already demonstrated the strength of combining highly sensitive MRD technology with our commercial infrastructure," said Mr. Lefkofsky. "With clinical adoption and reimbursement momentum building, we believe we are collectively well positioned to capture this opportunity, which makes this acquisition particularly exciting."
Second Quarter 2026 Summary Results
Revenue increased 22% year-over-year to $382.5 million.
Diagnostics generated $289.3 million of revenue, representing 20% year-over-year growth, driven by Oncology volume growth of 31%, offset by Hereditary revenue growth of 5%.
Data and Applications generated $93.2 million of revenue, representing 28% year-over-year growth, with Insights growing 36%.
Gross profit increased 26% year-over-year to $246.5 million, led by growth in Data and Applications.
Net income was $5.6 million, which included $55.6 million of stock compensation expense and related employer payroll taxes and $98.5 million in unrealized gains on marketable securities, compared to a net loss of $(42.8 million) in Q2 of 2025.
Adjusted EBITDA was $8.0 million, compared to ($5.6 million) in Q2 of 2025.
$820.7 million in cash and marketable securities as of June 30, 2026.
Recent Operational Highlights
Entered into a definitive agreement to acquire Personalis for $16.25 per share (~$1.5 billion enterprise value), tightly integrating its ultrasensitive NeXT Personal MRD technology into Tempus’ diagnostic platform
Received FDA approval for tumor-only xT CDx assay, becoming the first laboratory to hold FDA companion diagnostic (CDx) approval for both tumor-only and tumor-normal comprehensive genomic profiling
Launched digital pathology IMS Open-Source Consortium along with Yale New Haven Hospital (YNHH) and Memorial Sloan Kettering Cancer Center (MSK) to accelerate the democratization and standardization of digital pathology
Introduced Tempus Preview to provide preliminary results for high impact biomarkers within ~24 hours of tissue receipt
Announced a strategic collaboration with the Keck School of Medicine of USC to integrate Tempus’ AI platform, molecular diagnostics, and clinical trial matching across more than 1.5 million annual patient visits to accelerate precision oncology care
Introduced initial results from and successfully delivered the first version of our foundation model to AstraZeneca
Signed large deals with BioNTech, Daiichi Sankyo, Level Set Bio, and Incyte Pharmaceuticals, contributing to ~$200 million in total bookings this quarter
Second Quarter Financial Results
Three Months Ended June 30,
2026
2025
Change
(in thousands, except percentages and per share amounts)
(unaudited)
Revenue
$
382,486
$
314,635
22
%
Gross profit
$
246,498
$
195,039
26
%
Loss from operations
$
(75,913
)
$
(61,774
)
23
%
Non-GAAP loss from operations
$
(2,708
)
$
(17,036
)
(84
)%
Net income (loss)
$
5,642
$
(42,843
)
113
%
Non-GAAP net loss
$
(7,726
)
$
(37,327
)
(79
)%
Adjusted EBITDA
$
8,044
$
(5,580
)
244
%
Net income (loss) per share, basic
$
0.03
$
(0.25
)
112
%
Non-GAAP net loss per share, basic
$
(0.04
)
$
(0.22
)
(82
)%
Financial Outlook and Guidance
Tempus is increasing its full year 2026 revenue guidance to $1.595 to $1.605 billion, which represents ~25% annual growth. We continue to expect 2026 Adjusted EBITDA to be ~$65 million. Guidance assumes no impact from the Personalis transaction, which is expected to close in late Q4 2026 or early 2027.
For additional information on the quarter, including a letter from our CEO and CFO, please visit our investor relations site at investors.tempus.com.
Webcast and Conference Call Information
A conference call and webcast will begin today, July 30, 2026 after market close at 4:30 p.m. Eastern Time. Interested parties may access details at:
Conference ID: 9053038
United States – New York: (646) 307-1963
USA & Canada – Toll-Free: (800) 715-9871
Live webcast can be accessed here
The webcast may be accessed on the company’s investor relations website at investors.tempus.com. For those unable to listen to the live webcast, a recording will be made available on the company’s website after the event and will be accessible for one year. Visit the investor relations website to find the company’s latest deck, and commentary on the quarter by Eric Lefkofsky, Founder and CEO, and Jim Rogers, CFO, which will be discussed on the conference call and webcast.
(Press release, Tempus, JUL 30, 2026, View Source [SID1234669553])